Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, PB Watkins, ... Nature genetics 27 (4), 383-391, 2001 | 2699 | 2001 |
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ... New England Journal of Medicine 352 (22), 2285-2293, 2005 | 1821 | 2005 |
Genetic contribution to variable human CYP3A-mediated metabolism JK Lamba, YS Lin, EG Schuetz, KE Thummel Advanced drug delivery reviews 54 (10), 1271-1294, 2002 | 1218 | 2002 |
In vitro and in vivo drug interactions involving human CYP3A KE Thummel, GR Wilkinson Annual review of pharmacology and toxicology 38 (1), 389-430, 1998 | 1115 | 1998 |
Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism MF Paine, M Khalighi, JM Fisher, DD Shen, KL Kunze, CL Marsh, ... Journal of Pharmacology and Experimental Therapeutics 283 (3), 1552-1562, 1997 | 1023 | 1997 |
Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism KE Thummel, D O'Shea, MF Paine, DD Shen, KL Kunze, JD Perkins, ... Clinical Pharmacology & Therapeutics 59 (5), 491-502, 1996 | 724 | 1996 |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing KA Birdwell, B Decker, JM Barbarino, JF Peterson, CM Stein, W Sadee, ... Clinical Pharmacology & Therapeutics 98 (1), 19-24, 2015 | 655 | 2015 |
First‐pass metabolism of midazolam by the human intestine MF Paine, DD Shen, KL Kunze, JD Perkins, CL Marsh, JP McVicar, ... Clinical Pharmacology & Therapeutics 60 (1), 14-24, 1996 | 633 | 1996 |
Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation BM Kerr, KE Thummel, CJ Wurden, SM Klein, DL Kroetz, FJ Gonzalez, ... Biochemical pharmacology 47 (11), 1969-1979, 1994 | 580 | 1994 |
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism YS Lin, ALS Dowling, SD Quigley, FM Farin, J Zhang, J Lamba, ... Molecular pharmacology 62 (1), 162-172, 2002 | 563 | 2002 |
Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by … P Schmiedlin-Ren, DJ Edwards, ME Fitzsimmons, K He, KS Lown, ... Drug Metabolism and Disposition 25 (11), 1228-1233, 1997 | 488 | 1997 |
Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test KS Lown, JC Kolars, KE Thummel, JL Barnett, KL Kunze, SA Wrighton, ... Drug Metabolism and Disposition 22 (6), 947-955, 1994 | 465 | 1994 |
Mutual repression between steroid and xenobiotic receptor and NF-κB signaling pathways links xenobiotic metabolism and inflammation C Zhou, MM Tabb, EL Nelson, F Grün, S Verma, A Sadatrafiei, M Lin, ... The Journal of clinical investigation 116 (8), 2280-2289, 2006 | 451 | 2006 |
Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α, 25-dihydroxyvitamin D3 P Schmiedlin-Ren, KE Thummel, JM Fisher, MF Paine, KS Lown, ... Molecular pharmacology 51 (5), 741-754, 1997 | 433 | 1997 |
Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. ED Kharasch, KE Thummel Anesthesiology 79 (4), 795-807, 1993 | 424 | 1993 |
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process SM Huang, JM Strong, L Zhang, KS Reynolds, S Nallani, R Temple, ... The Journal of clinical pharmacology 48 (6), 662-670, 2008 | 421 | 2008 |
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. KE Thummel, DD Shen, TD Podoll, KL Kunze, WF Trager, PS Hartwell, ... Journal of Pharmacology and Experimental Therapeutics 271 (1), 549-556, 1994 | 420 | 1994 |
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction KE Thummel, KL Kunze, DD Shen Advanced drug delivery reviews 27 (2-3), 99-127, 1997 | 406 | 1997 |
Transcriptional control of intestinal cytochrome P-4503A by 1α, 25-dihydroxy vitamin D3 KE Thummel, C Brimer, K Yasuda, J Thottassery, T Senn, Y Lin, ... Molecular Pharmacology 60 (6), 1399-1406, 2001 | 402 | 2001 |
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations JK Lamba, YS Lin, K Thummel, A Daly, PB Watkins, S Strom, J Zhang, ... Pharmacogenetics and Genomics 12 (2), 121-132, 2002 | 398 | 2002 |